Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last CNY66.50 CNY
Change Today +2.94 / 4.63%
Volume 2.1M
As of 3:00 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

livzon pharmaceutical grou-a (000513) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/15 - CNY99.43
52 Week Low
08/21/14 - CNY46.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LIVZON PHARMACEUTICAL GROU-A (000513)

Related News

No related news articles were found.

livzon pharmaceutical grou-a (000513) Related Businessweek News

No Related Businessweek News Found

livzon pharmaceutical grou-a (000513) Details

Livzon Pharmaceutical Group Inc. engages in the research and development, production, and sale of pharmaceutical products in the People’s Republic of China. Its products primarily include Chinese and Western drug preparation products, such as Shengqi Fuzheng Injection, a series of Bismuth Potassium Citrate Granules products, anti-viral granules, Urofollitropin for injection, Menotropins for injection, Ilaprazole, Voriconazole for injection, mouse nerve growth factor for injection, and Leuprorelin Acetate Microspheres for injection. The company’s products also comprise bulk medicines and intermediates, including Mevastatin, Colistin, Phenylalanine, Ceftriaxone Sodium, Cefuroxime Sodium, and Cefodizime Sodium; and diagnostic reagent products, such as ELISA HIV testing reagent, MYCOII testing reagent, and TPPA testing reagent. In addition, the company provides chemical drugs, biochemical drugs, microbiological preparations, and antibiotics; polypeptide bulk medicines; diagnostic reagents and equipment; human menopausal gonadotropin and human chorionic gonadotropin medicines; Omeprazole Sodium for injection; Ranitidine Bismuth Citrate tablets; Valaciclovir Hydrochloride tablets; Fluvoxamine Maleate tablet; Perospirone Hydrochloride tablets; and Prostant used for the treatment of clearing away heat evil and promoting diuresis. Further, it offers specialist bulk medicines and intermediates, such as fermented antibiotics, sterile cephalosporins, and hypolipidemic stantins. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.

Founded in 1985

livzon pharmaceutical grou-a (000513) Top Compensated Officers

Vice Chairman, President, Member of Nominatio...
Total Annual Compensation: CNY790.6K
Chief Financial Officer and Vice President
Total Annual Compensation: CNY529.4K
Vice President and Executive Director
Total Annual Compensation: CNY589.3K
Chief Supervisor of the Legal Supervision Hea...
Total Annual Compensation: CNY294.8K
Company Secretary
Total Annual Compensation: CNY232.9K
Compensation as of Fiscal Year 2014.

livzon pharmaceutical grou-a (000513) Key Developments

Livzon Pharmaceutical Group Inc. Approves Cash Dividend for the Year 2014

Livzon Pharmaceutical Group Inc. announced at AGM held on June 26, 2015, the shareholders of the company approved the cash dividend of CNY 1.00000000 per 10 shares under 2014 profit distribution plan.

Livzon Pharmaceutical Group Inc. Announces Executive Changes

Livzon Pharmaceutical Group Inc. announced that Mr. Yang Bin retired as an Independent Non-executive Director of the company due to the expiration of his tenure as a director, and ceased to be the Chairman of Nomination Committee and a member of Audit Committee of the company following his retirement. Mr. Yang Bin has confirmed that he has no disagreement with the Board and there are no matters relating to his retirement that need to be brought to the attention of the shareholders of the company. At the company's Annual General Meeting for the year 2014 (the AGM) held on 26 June 2015, Mr. Zheng Zhihua (Mr. Zheng) and Mr. Xie Yun (Mr. Xie) were appointed as Independent Non-executive Directors for the eighth session of the Board, whose tenures both commence from the date of passing of the relevant resolutions at the AGM (i.e. 26 June 2015) and end on the expiration of the tenure of the eighth session of the Board. Mr. Xie was appointed as the Chairman of Nomination Committee and a member of Audit Committee of the eighth session of the Board, whose tenure commences from the date of passing of the relevant resolution at the twelveth meeting of the eighth session of the Board (i.e. 26 June 2015) and ends on the expiration of the tenure of the eighth session of the Board. The positions held by other members of the eighth session of the Board in the four committees of the Board remain unchanged. Zheng Zhihua Han ethnic, a member of Communist Party of China. He graduated from Medical Enterprises Management, China Pharmaceutical University with a Bachelor of Science degree in 1992. Xie Yun, master degree holder, senior economist, accountant. He worked as an office director and financial manager in Zhuhai Airport Power Station Limited company from August 1993 to March 1997. Mr. Zheng and Mr. Xie have not taken up any other positions in the company or any of its subsidiaries. Mr. Zheng has not held any directorship in other listed companies in the present and last three years preceding the date of this announcement; Mr. Xie has held directorship in Zhuhai Wan LiDa Electric Co. Ltd. and Leaguer StockCo. Ltd.from August 2010 to October 2014 and from May 2011 to May 2014 respectively.

Livzon Pharmaceutical Group Inc. to Build Biodegradable Micro-Sphere Research Center

Livzon Pharmaceutical Group Inc. declared approval from the National Development and Reform Commission for the listed company to build Biodegradable Micro-sphere Joint Engineering Research Center. Biodegradable micro-sphere preparations belong to biomedicines born at the end of last century, lowering frequencies for taking drugs and stabilizing blood concentration to improve curing effect and reduce toxic and side effects, let alone increasing drug stability and obedience by patients, reducing their pains and medical costs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
000513:CH CNY66.50 CNY +2.94

000513 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 000513.
View Industry Companies

Industry Analysis


Industry Average

Valuation 000513 Industry Range
Price/Earnings 33.8x
Price/Sales 3.2x
Price/Book 4.5x
Price/Cash Flow 22.0x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIVZON PHARMACEUTICAL GROU-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at